000124412 001__ 124412
000124412 005__ 20240228145513.0
000124412 0247_ $$2doi$$a10.18632/oncotarget.14380
000124412 0247_ $$2pmid$$apmid:28052012
000124412 0247_ $$2pmc$$apmc:PMC5354655
000124412 037__ $$aDKFZ-2017-01291
000124412 041__ $$aeng
000124412 082__ $$a610
000124412 1001_ $$0P:(DE-He78)33beb55034049b5d9833135ad1e0e3d2$$aTsai, Ming-Han$$b0$$eFirst author
000124412 245__ $$aThe biological properties of different Epstein-Barr virus strains explain their association with various types of cancers.
000124412 260__ $$a[S.l.]$$bImpact Journals LLC$$c2017
000124412 3367_ $$2DRIVER$$aarticle
000124412 3367_ $$2DataCite$$aOutput Types/Journal article
000124412 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1511256864_9860
000124412 3367_ $$2BibTeX$$aARTICLE
000124412 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000124412 3367_ $$00$$2EndNote$$aJournal Article
000124412 520__ $$aThe Epstein-Barr virus (EBV) is etiologically associated with the development of multiple types of tumors, but it is unclear whether this diversity is due to infection with different EBV strains. We report a comparative characterization of SNU719, GP202, and YCCEL1, three EBV strains that were isolated from gastric carcinomas, M81, a virus isolated in a nasopharyngeal carcinoma and several well-characterized laboratory type A strains. We found that B95-8, Akata and GP202 induced cell growth more efficiently than YCCEL1, SNU719 and M81 and this correlated positively with the expression levels of the viral BHRF1 miRNAs. In infected B cells, all strains except Akata and B95-8 induced lytic replication, a risk factor for carcinoma development, although less efficiently than M81. The panel of viruses induced tumors in immunocompromised mice with variable speed and efficacy that did not strictly mirror their in vitro characteristics, suggesting that additional parameters play an important role. We found that YCCEL1 and M81 infected primary epithelial cells, gastric carcinoma cells and gastric spheroids more efficiently than Akata or B95-8. Reciprocally, Akata and B95-8 had a stronger tropism for B cells than YCCEL1 or M81. These data suggest that different EBV strains will induce the development of lymphoid tumors with variable efficacy in immunocompromised patients and that there is a parallel between the cell tropism of the viral strains and the lineage of the tumors they induce. Thus, EBV strains can be endowed with properties that will influence their transforming abilities and the type of tumor they induce.
000124412 536__ $$0G:(DE-HGF)POF3-316$$a316 - Infections and cancer (POF3-316)$$cPOF3-316$$fPOF III$$x0
000124412 588__ $$aDataset connected to CrossRef, PubMed,
000124412 7001_ $$0P:(DE-He78)da1a557349f25c641b1a368af5b218a7$$aLin, Xiaochen$$b1
000124412 7001_ $$0P:(DE-He78)6848fb449349189d3fde6a1667392cec$$aShumilov, Anatoliy$$b2
000124412 7001_ $$0P:(DE-He78)944cafd16d8f74f63b6b7039c6407dc5$$aBernhardt, Katharina$$b3
000124412 7001_ $$0P:(DE-He78)ac9bd330be3905c47d74d99f48793191$$aFeederle, Regina$$b4$$udkfz
000124412 7001_ $$0P:(DE-He78)27152949302e3bd0d681a6f0548912b9$$aPoirey, Remy$$b5
000124412 7001_ $$0P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aKopp-Schneider, Annette$$b6
000124412 7001_ $$aPereira, Bruno$$b7
000124412 7001_ $$aAlmeida, Raquel$$b8
000124412 7001_ $$0P:(DE-He78)25d3c74b949988c637571e696fc04b25$$aDelecluse, Henri-Jacques$$b9$$eLast author
000124412 773__ $$0PERI:(DE-600)2560162-3$$a10.18632/oncotarget.14380$$gVol. 8, no. 6$$n6$$p10238-10254$$tOncoTarget$$v8$$x1949-2553$$y2017
000124412 909CO $$ooai:inrepo02.dkfz.de:124412$$pVDB
000124412 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)33beb55034049b5d9833135ad1e0e3d2$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000124412 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)da1a557349f25c641b1a368af5b218a7$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000124412 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6848fb449349189d3fde6a1667392cec$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000124412 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)944cafd16d8f74f63b6b7039c6407dc5$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000124412 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ac9bd330be3905c47d74d99f48793191$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000124412 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)27152949302e3bd0d681a6f0548912b9$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000124412 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000124412 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)25d3c74b949988c637571e696fc04b25$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000124412 9131_ $$0G:(DE-HGF)POF3-316$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfections and cancer$$x0
000124412 9141_ $$y2017
000124412 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bONCOTARGET : 2015
000124412 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000124412 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000124412 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000124412 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000124412 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000124412 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000124412 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000124412 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bONCOTARGET : 2015
000124412 9201_ $$0I:(DE-He78)F100-20160331$$kF100$$lPathogenese infektionsbedingter Tumoren$$x0
000124412 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000124412 980__ $$ajournal
000124412 980__ $$aVDB
000124412 980__ $$aI:(DE-He78)F100-20160331
000124412 980__ $$aI:(DE-He78)C060-20160331
000124412 980__ $$aUNRESTRICTED